Monogram Technologies Inc. Files Q2 2025 10-Q

TL;DR

Monogram Tech 10-Q filed. Financials updated for Q2 2025.

AI Summary

Monogram Technologies Inc. filed its 10-Q for the period ending June 30, 2025. The company, formerly Monogram Orthopaedics Inc., is involved in surgical and medical instruments. Financial details such as retained earnings and additional paid-in capital are reported as of various dates throughout 2024 and 2025.

Why It Matters

This filing provides investors with an update on Monogram Technologies Inc.'s financial position and performance for the second quarter of 2025, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a 10-Q filing, it contains detailed financial information that can reveal significant performance trends or risks for investors.

Key Numbers

• 3537000 — Common Stock (Reported as of various dates in 2024 and 2025)
• 4361249 — Series D Preferred Stock (Reported as of various dates in 2024 and 2025)
• 229000 — Retained Earnings (Reported as of June 30, 2025)

Key Players & Entities

• Monogram Technologies Inc. (company) — Filer of the 10-Q
• Monogram Orthopaedics Inc. (company) — Former name of Monogram Technologies Inc.
• June 30, 2025 (date) — End of the reporting period
• 20250815 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value per share MGRM The Nasdaq
• $4.04 — of Common Stock, an amount equal to (i) $4.04 per share (the "Cash Amount") without i
• $2.25 — s D Preferred Stock, an amount equal to $2.25 per share, in cash, without interest an
• $100.00 — s E Preferred Stock, an amount equal to $100.00 per share, in cash, without interest an
• $1.04 — one payment triggers, a cash payment of $1.04 per CVR for the First Milestone, $1.08
• $1.08 — $1.04 per CVR for the First Milestone, $1.08 per CVR for the Second Milestone, up to
• $3.41 — per CVR for the Second Milestone, up to $3.41 per CVR for the Third Milestone, up to
• $3.43 — CVR for the Fourth Milestone and up to $3.43 per CVR for the Fifth Milestone. The ca

Filing Documents

• mgrm-20250630x10q.htm (10-Q) — 944KB
• mgrm-20250630xex31d1.htm (EX-31.1) — 9KB
• mgrm-20250630xex31d2.htm (EX-31.2) — 9KB
• mgrm-20250630xex32d1.htm (EX-32.1) — 5KB
• mgrm-20250630xex32d2.htm (EX-32.2) — 5KB
• 0001410578-25-001836.txt ( ) — 3795KB
• mgrm-20250630.xsd (EX-101.SCH) — 31KB
• mgrm-20250630_cal.xml (EX-101.CAL) — 31KB
• mgrm-20250630_def.xml (EX-101.DEF) — 124KB
• mgrm-20250630_lab.xml (EX-101.LAB) — 285KB
• mgrm-20250630_pre.xml (EX-101.PRE) — 221KB
• mgrm-20250630x10q_htm.xml (XML) — 373KB

Financial Statements

Financial Statements 4 Condensed Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 4 Condensed Statements of Operations for the three and six months ended June 30, 2025 and June 30, 2024 (Unaudited) 5 Condensed Statements of Stockholders' Equity for the three and six months ended June 30, 2025 and June 30, 2024 (Unaudited) 6 Condensed Statements of Cash Flows for the six months ended June 30, 2025 and June 30, 2024 (Unaudited) 7

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 22 Item 4.

Controls and Procedures

Controls and Procedures 22 PART II. OTHER INFORMATION 24 Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sale of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 27 Item 4. Mine Safety Disclosures 27 Item 5. Other Information 27 Item 6. Exhibits 28

Signatures

Signatures 31 2 Table of Contents Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially and adversely from those expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to our outlook or expectations for earnings, revenues, expenses, asset quality or other future financial or business performance, strategies, expectations or business prospects, or the impact of legal, regulatory or supervisory matters on our business, results of operations, or financial condition. Specifically, forward-looking statements may include statements relating to our future business prospects, revenue, income, and financial condition. Forward-looking statements can be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "target," or similar expressions. Forward-looking statements reflect our judgment based on currently available information and involve a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements contained in this Form 10-Q include, but are not limited to, statements about: the structure, timing and ability to consummate the Merger; any anticipated effects of the Merger's announcement, pendency or completion on the value of our common stock; our ability to obtain the Stockholder Approval (as defined below) or our or Zimmer Biomet's ability to obtain any required regulatory or stock

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements MONOGRAM TECHNOLOGIES INC. CONDENSED BALANCE SHEETS (in thousands, except share and per share amounts) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 12,834 $ 15,658 Prepaid expenses and other current assets 624 625 Total current assets 13,458 16,283 Equipment, net of accumulated depreciation 1,033 810 Intangible assets, net 234 339 Operating lease right-of-use assets 273 338 Total assets $ 14,998 $ 17,770 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,317 $ 1,174 Accrued liabilities 4,768 229 Operating lease liabilities, current 143 138 Total current liabilities 6,228 1,541 Operating lease liabilities, non-current 153 226 Other liabilities — 1,500 Total liabilities 6,381 3,267 Commitments and contingencies — — Stockholders' equity: Series D Preferred Stock, $ 0.001 par value; 6,000,000 shares authorized; 4,187,569 and 4,361,249 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of $ 9,422 and $ 9,812 at June 30, 2025 and December 31, 2024, respectively 4 4 Common stock, $ .001 par value; 90,000,000 shares authorized, 36,088,725 and 35,167,673 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 36 35 Additional paid-in capital 85,586 82,452 Accumulated deficit ( 77,009 ) ( 67,988 ) Total stockholders' equity 8,617 14,503 Total liabilities and stockholders' equity $ 14,998 $ 17,770 The accompanying notes are an integral part of these financial statements. 4 Table of Contents MONOGRAM TECHNOLOGIES INC. CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except share and per share amounts) Three months ended Six months ended June 30, June 30, 2025 2024 2025 2024 Product revenue $ — $ — $ — $ —

View Full Filing

View this 10-Q filing on SEC EDGAR